A Prospective Study of Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy in Patients With Esophageal Squamous Cell Carcinoma

Condition:   Esophageal Squamous Cell Carcinoma
Intervention:   Combination Product: Apatinib,Paclitaxel,Cisplatin,RT
Sponsor:   Hebei Medical University Fourth Hospital
Not yet recruiting

https://ift.tt/2EiImBP